Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1-targeted CAR-T for Relapsed Multiple Myeloma
NCT04541368Phase 1Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UCARTCS1 in multiple myeloma (MM), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Incidence of treatment-emergent adverse events at 2 years. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
UCARTCS1
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04541368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541368.